CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Midazolam +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05032950
NCT05032950Phase 1Completed
CompareCT.gov

COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY PARTICIPANTS.

Pfizer·interventional·Posted Sep 2, 2021·Updated Oct 4, 2023

In Brief

A Phase 1 clinical trial evaluating Midazolam, PF-07321332/ritonavir + Midazolam, and 1 other intervention for Healthy Participants. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 \[CYP\]3A4 substrate) in Healthy Adult Participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedSep 2, 2021
Enrollment StartSep 17, 2021
Primary CompletionDec 9, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.8 years ago

Interventions

Midazolamdrug

Midazolam administered as a single dose on Day 1

PF-07321332/ritonavir + Midazolamdrug

PF-07321332/ritonavir: Administered orally every 12 hours for a total of 9 doses on Days 1-5 Midazolam: Administered orally as a single dose on Day 5

Ritonavir + Midazolamdrug

Ritonavir: Administered orally every 12 hours for a total of 9 doses on Day1-5. Midazolam: Administered orally as a single dose on Day 5